Mark Opdam

1.3k citations

32 papers · 583 · h-index 15

Impact in

Cancer Research top 10%
- Cancer-related molecular mechanisms research
- Breast Cancer Treatment Studies
Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research

Papers in

Molecular Biology 13
- PI3K/AKT/mTOR signaling in cancer 8
Oncology 9
- Cancer Immunotherapy and Biomarkers 3
- HER2/EGFR in Cancer Research 3

Co-authors: Sabine C. Linn (26 shared papers)Karin Beelen (9 shared papers)P. J. van Diest (8 shared papers)Jelle Wesseling (10 shared papers)Joyce Sanders (8 shared papers)Andrew Vincent (6 shared papers)Tesa Severson (5 shared papers)Vincent van der Noort (5 shared papers)
Journals: Annals of Oncology (4 papers)Breast Cancer Research (4 papers)European Journal of Cancer (3 papers)Cancer Research (2 papers)Breast Cancer Research and Treatment (2 papers)
Partner nations: Netherlands Belgium Germany

In The Last Decade

Mark Opdam

31 papers receiving 574 citations

Peers

Countries citing papers authored by Mark Opdam

Since Specialization

Citations

This map shows the geographic impact of Mark Opdam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Opdam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Opdam more than expected).

Fields of papers citing papers by Mark Opdam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Opdam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Opdam. The network helps show where Mark Opdam may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Opdam, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Opdam Line = papers co-authored together Mark Opdam links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 32 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes Breast Cancer Research ·Marcelo Sobral‐Leite, Izhar Salomon, Mark Opdam, Dinja T. Kruger, Karin Beelen, Vincent van der Noort, Ronald L. P. van Vlierberghe, Erik J. Blok, Daniele Giardiello, Joyce Sanders, Koen Van de Vijver, Hugo M. Horlings, Peter J.K. Kuppen, Sabine C. Linn, Marjanka K. Schmidt, Marleen Kok	2019	87
2	Deep learning-based breast cancer grading and survival analysis on whole-slide histopathology images Scientific Reports ·Suzanne C. Wetstein, Vincent M. T. de Jong, Nikolas Stathonikos, Mark Opdam, Gwen Dackus, Josien P. W. Pluim, P. J. van Diest, Mitko Veta	2022	58
3	PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients Breast Cancer Research ·Karin Beelen, Mark Opdam, Tesa Severson, Rutger H.T. Koornstra, Andrew Vincent, Jelle Wesseling, Jettie J.F. Muris, Els M.J.J. Berns, Jan B. Vermorken, P. J. van Diest, Sabine C. Linn	2014	47
4	High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1 -like Breast Cancer Molecular Cancer Therapeutics ·Philip C. Schouten, Marieke A. Vollebergh, Mark Opdam, Martijn Jonkers, Martin Lodén, Jelle Wesseling, Michael Hauptmann, Sabine C. Linn	2015	43
5	Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment Breast Cancer Research ·Karin Beelen, Mark Opdam, Tesa Severson, Rutger H.T. Koornstra, Andrew Vincent, Jelle Wesseling, Jettie J.F. Muris, Els M.J.J. Berns, Jan B. Vermorken, P. J. van Diest, Sabine C. Linn	2014	36
6	4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer Molecular Oncology ·Tommaso De Marchi, Ning Qing Liu, Cristoph Stingl, Mieke Timmermans, Marcel Smid, Maxime P. Look, Mila Tjoa, René B. H. Braakman, Mark Opdam, Sabine C. Linn, Fred C.G.J. Sweep, Paul N. Span, Mike Kliffen, Theo M. Luider, John A. Foekens, John W.M. Martens, Arzu Umar	2015	33
7	Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas Cancer Research ·Marjolein Droog, Ekaterina Nevedomskaya, Yongsoo Kim, Tesa Severson, Koen D. Flach, Mark Opdam, Karianne Schuurman, Patrycja Gradowska, Michael Hauptmann, Gwen Dackus, Harry Hollema, Marian J.E. Mourits, Petra M. Nederlof, Hester van Boven, Sabine C. Linn, Lodewyk F.A. Wessels, Flora E. van Leeuwen, Wilbert Zwart	2016	27
8	PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy International Journal of Cancer ·Karin Beelen, Laurien D.C. Hoefnagel, Mark Opdam, Jelle Wesseling, Joyce Sanders, Andrew Vincent, P. J. van Diest, Sabine C. Linn	2014	26
9	IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer International Journal of Cancer ·Dinja T. Kruger, Xanthippi Alexi, Mark Opdam, Karianne Schuurman, Leonie Voorwerk, Joyce Sanders, Vincent van der Noort, Epie Boven, Wilbert Zwart, Sabine C. Linn	2019	23
10	Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer Oncotarget ·Tommaso De Marchi, Anne Timmermans, Marcel Smid, Maxime P. Look, Christoph Stingl, Mark Opdam, Sabine C. Linn, Fred C.G.J. Sweep, Paul N. Span, Mike Kliffen, Carolien H. M. van Deurzen, Theo M. Luider, John A. Foekens, John W.M. Martens, Arzu Umar	2015	22
11	CYP2C192 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment Breast Cancer Research and Treatment* ·Karin Beelen, Mark Opdam, Tesa Severson, Rutger H.T. Koornstra, Andrew Vincent, Michael Hauptmann, Ron H. N. van Schaik, E. Berns, Jan B. Vermorken, P. J. van Diest, Sabine C. Linn	2013	21
12	Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences British Journal of Cancer ·Dinja T. Kruger, Karin Beelen, Mark Opdam, Joyce Sanders, Vincent van der Noort, Epie Boven, Sabine C. Linn	2018	18
13	Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy European Journal of Cancer ·Leonora W. de Boo, Ashley Cimino‐Mathews, Yoni Lubeck, Antonios Daletzakis, Mark Opdam, Joyce Sanders, Erik Hooijberg, Annelot van Rossum, Zuzana Loncová, Dietmar Rieder, Zlatko Trajanoski, Marieke A. Vollebergh, Marcelo Sobral‐Leite, Koen Van de Vijver, Annegien Broeks, R Wiel, Harm van Tinteren, Sabine C. Linn, Hugo M. Horlings, Marleen Kok	2020	18
14	Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera Journal of Proteome Research ·Tommaso De Marchi, Erik Kuhn, Lennard J. M. Dekker, Christoph Stingl, René B. H. Braakman, Mark Opdam, Sabine C. Linn, Fred C.G.J. Sweep, Paul N. Span, Theo M. Luider, John A. Foekens, John W.M. Martens, Steven A. Carr, Arzu Umar	2016	17
15	159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group Annals of Oncology ·Vincent M. T. de Jong, Y. Wang, Mark Opdam, ND ter Hoeve, Katarzyna Jóźwiak, Michael Hauptmann, Nikolas Stathonikos, Hugo M. Horlings, Annegien Broeks, Stefan Michiels, Elsken van der Wall, Paul van Diest, Sabine Siesling, Marjanka K. Schmidt, Shrushma Loi, M. Kok, Sabine C. Linn, Roberto Salgado, Gwen Dackus	2020	16
16	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer Clinical Cancer Research ·Wilbert Zwart, Koen D. Flach, Bharath Rudraraju, Tarek M.A. Abdel-Fatah, Ondřej Gojiš, Sander Canisius, David T. Moore, Ekaterina Nevedomskaya, Mark Opdam, Marjolein Droog, Ingrid Hofland, (unknown), Jacqui Shaw, Ian O. Ellis, R. Charles Coombes, Jason S. Carroll, Simak Ali, Carlo Palmieri	2015	14
17	Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients British Journal of Cancer ·Leonora W. de Boo, Katarzyna Jóźwiak, Heikki Joensuu, Henrik Lindman, Susanna Lauttia, Mark Opdam, Charlaine van Steenis, Wim Brugman, Roelof J.C. Kluin, Philip C. Schouten, Marleen Kok, Petra M. Nederlof, Michael Hauptmann, Sabine C. Linn	2022	11
18	Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04) European Journal of Cancer ·Annelot G.J. van Rossum, Marleen Kok, Erik van Werkhoven, Mark Opdam, Ingrid A.M. Mandjes, A. Elise van Leeuwen – Stok, Harm van Tinteren, Alexander L.T. Imholz, Johanneke E.A. Portielje, Monique M.E.M. Bos, Aart van Bochove, Jelle Wesseling, Emiel J. Rutgers, Sabine C. Linn, Hendrika M. Oosterkamp	2018	10
19	Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system OncoImmunology ·Sjoerd Klarenbeek, Chris W. Doornebal, Sjors M. Kas, Nicola Bonzanni, Jinhyuk Bhin, Tanya M. Braumuller, Ingrid van der Heijden, Mark Opdam, Philip C. Schouten, Kelly Kersten, Roebi de Bruijn, Daniel Zingg, Julia Yemelyanenko, Lodewyk F.A. Wessels, Karin E. de Visser, Jos Jonkers	2020	9
20	FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer Cell Reports ·Sandra Tavares, Nalan Liv, Milena Pasolli, Mark Opdam, Max A. K. Rätze, Manuel Saornil, Lilian Sluimer, Rutger C.C. Hengeveld, Robert van Es, Erik van Werkhoven, Harmjan R. Vos, Holger Rehmann, Boudewijn Burgering, Hendrika M. Oosterkamp, Susanne M.A. Lens, Judith Klumperman, Sabine C. Linn, Patrick W.B. Derksen	2022	7

About Mark Opdam

Mark Opdam is a scholar working on Molecular Biology, Oncology, Genetics, Cancer Research and Pulmonary and Respiratory Medicine, having authored 32 papers that have together received 583 indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (8 papers), Estrogen and related hormone effects (5 papers), Breast Cancer Treatment Studies (4 papers), Cancer Immunotherapy and Biomarkers (3 papers), HER2/EGFR in Cancer Research (3 papers), Cancer Genomics and Diagnostics (2 papers), Advanced Proteomics Techniques and Applications (2 papers) and BRCA gene mutations in cancer (2 papers). The work is most often cited by research in Cancer Research (157 citations), Oncology (217 citations), Molecular Biology (257 citations), Pulmonary and Respiratory Medicine (74 citations) and Genetics (67 citations). Mark Opdam has collaborated with scholars based in Netherlands, Belgium and Germany. Frequent co-authors include Sabine C. Linn, Karin Beelen, P. J. van Diest, Jelle Wesseling, Joyce Sanders, Andrew Vincent, Tesa Severson, Vincent van der Noort, Michael Hauptmann and Rutger H.T. Koornstra. Their work appears in journals such as Annals of Oncology, Breast Cancer Research, European Journal of Cancer, Cancer Research and Breast Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark Opdam

Impact in

Papers in i

In The Last Decade

Mark Opdam

Peers

Countries citing papers authored by Mark Opdam

Fields of papers citing papers by Mark Opdam

All Works

About Mark Opdam

Explore authors with similar magnitude of impact

Papers in